Aperiam Bio

Aperiam Bio is a protein engineering company that utilizes a patented, 3D computer vision algorithm to identify targeted improvements in proteins, effectively functioning like facial recognition technology for molecular structures. By analyzing the local chemical environment of amino acids within a folded protein, the company identifies and modifies residues that do not optimally fit, creating hyperfolding variants with significantly improved expression, solubility, and specific activity. This approach enables the company to bypass traditional, more labor-intensive methods of protein engineering, producing more stable and durable proteins that can withstand chemical, thermal, and mechanical stresses better than their natural counterparts.

The company's technology has diverse applications, ranging from technical reagents for manufacturing and shelf-stable enzymes for the cosmetics industry to specialized therapeutics for pulmonary applications. By optimizing protein stability, Aperiam Bio enables new product categories, such as proteins that retain high activity levels during nebulization for lung-based drug delivery. Founded in 2021 based on research from the University of Texas, the company partners with industry collaborators to develop these enhanced protein solutions and has secured seed funding to advance its research and development initiatives.